- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07949916
Immunogenicity and Safety of Vaccination Against Tick Borne Encephalitis (TBE) in Patients Living With Multiple Sclerosis (MS) (MS and TBE vac)
This is a monocenter, prospective cohort study. The study investigates the response of patients living with multiple sclerosis (MS) to vaccination against tick-borne viral encephalitis (TBE).
The prevalence of TBE has increased significantly in Switzerland over the past two decades. Whereas previously only the lowland regions of northern Switzerland and the Aare Valley were considered areas where TBE vaccination was indicated, the disease is now endemic throughout Switzerland (except for Ticino). Since TBE specifically affects the nervous system, there is a clear indication for vaccination, particularly for people whose nervous system is already compromised.
MS is the most common neurological autoimmune disease among young adults in northern latitudes. It is a progressive disease characterized by a gradual deterioration of neurological functions. The course of the disease can be slowed through immunomodulatory therapies. However, these therapies also lead to a certain degree of immunosuppression, which may reduce the immune response to vaccinations. At the same time, some people with MS experience fear or scepticism towards vaccinations, as infections often lead to a worsening of symptoms or can trigger a relapse. Since vaccinations mimic an infection to some extent, this concern is sometimes transferred to vaccinations as well.
The study hypothesizes that the TBE vaccine in people living with MS on non-B-cell depleting treatment shows adequate immunogenicity.
Moreover, the study will assess the safety of TBE vaccination.
Studieoversikt
Status
Forhold
Studietype
Registrering (Antatt)
Kontakter og plasseringer
Studiekontakt
- Navn: Cornelia Staehelin, PD. Dr. med.
- Telefonnummer: +41 31 632 01 83
- E-post: cornelia.staehelin@insel.ch
Studer Kontakt Backup
- Navn: Robert Hoepner, Prof. Dr. med.
- Telefonnummer: +41 316325835
- E-post: robert.hoepner@insel.ch
Studiesteder
-
-
-
Bern, Sveits, 3010
- Rekruttering
- University Hospital of Bern
-
Ta kontakt med:
- Cornelia Staehelin, PD Dr. med
- Telefonnummer: +41 31 632 01 83
- E-post: cornelia.staehelin@insel.ch
-
Ta kontakt med:
- Robert Hoepner, PD Dr. med.
- Telefonnummer: +41 +41 632 60 93
- E-post: robert.hoepner@insel.ch
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
The investigators target a sample size of 50 people living with MS with stable RRMS (no evidence of disease activity -NEDA-3 status - as defined by no clinical relapse, no EDSS worsening and no new MS-lesions on MRI) for ≥ 1 year prior to inclusion into the study and treated with non-B-cell depleting therapies for at least 6 months in monotherapy.
In order to have a homogenous and stable patient population, the investigators decided to include only patients without evidence of disease activity for at least 1 year prior to inclusion. Considering the latter the investigators classify any disease reactivation during the period of 42 days (+/- 7days) after the first dose / booster dose as related to the intervention (vaccination).
Beskrivelse
Inclusion Criteria
-
Adult (≥ 18 years old)
-
Suspected neuroimmunological disorder with CNS affection
- including suspicion of Multiple Sclerosis (MS)
- Diagnosed Multiple Sclerosis (MS)
- Clinically Isolated Syndrome
- Radiologically Isolated Syndrome
-
stable RRMS - defined as no evidence of disease activity-NEDA-3 status-as defined by no clinical relapse, no EDSS worsening and no new MS-lesions on MRI for ≥ 1 year prior to inclusion
-
treated with non-B-cell depleting therapies for at least 6 months in monotherapy
-
TBE vaccine:
- never been vaccinated against TBE or
- clinical indication for booster vaccination (person living with MS and has had primary series of 3 vaccines of which the last one was ≥ 10 years ago)
-
Provided written informed consent
Exclusion Criteria
- Any B-cell depleting therapies in last 12 months prior to recruitment
- Any other vaccination in last 2 months prior to recruitment
- Any foreseeable and necessary other vaccination up to 42 days post dose 1
- Immunoglobulin-Infusion (intravenous or subcutaneous, IVIG or SCIG) in the last 4 months prior to the drawing of study samples
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: COHORT
- Tidsperspektiver: PROSPECTIVE
Kohorter og intervensjoner
Gruppe / Kohort |
|---|
|
Primary vaccination series or Booser against TBE in patients with MS
According to Swiss guidelines, patients with MS will receive the primary vaccination series (3 doses) against TBE (if they have never been vaccinated) or a TBE booster (if they have already received the primary vaccination series and their last vaccination was ≥ 10 years ago). |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Primary immunogenicity endpoint
Tidsramme: 42 days post dose 1
|
Change in antibody concentration (GMC) from baseline to day 42 post dose 1 as measured by ELISA |
42 days post dose 1
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Immunogenicity endpoint
Tidsramme: 42 days post dose 1
|
Change in antibody titers as measured by serum neutralizing test (SNT) from baseline to day 42 (post dose 1) |
42 days post dose 1
|
|
Immunogenicity endpoint
Tidsramme: 7 months post dose 1 or 6 months post booster dose
|
Change in antibody titers as measured by ELISA from baseline to week 9 and month 7 post dose 1 if primary vaccination resp. from baseline to month 6 post booster dose. |
7 months post dose 1 or 6 months post booster dose
|
|
Immunogenicity endpoint
Tidsramme: 7 months post dose 1 or 6 months post booster dose
|
Change in antibody titers as measured by SNT from baseline to week 9 and month 7 post dose 1 if primary vaccination resp. from baseline to month 6 post booster dose. |
7 months post dose 1 or 6 months post booster dose
|
|
Immunogenicity endpoint
Tidsramme: at each time point (7 months)
|
Seropositivity as measured by ELISA . Seropositivity is defined as IgG antibody concentration >150 U/ml for ELISA. |
at each time point (7 months)
|
|
Immunogenicity endpoint
Tidsramme: at each time point (7 months)
|
Seropositivity as measured by SNT at each time point. Seropositivity is defined as antibody titer >1:10 for SNT. |
at each time point (7 months)
|
|
Safety endpoint
Tidsramme: 42 (+/-7d) post dose 1
|
The investigators will analyse indicators of disease activity through different indicators only up to day 42 (+/-7d) post dose 1 - Incidence of MS-relapses - defined clinically, according to clinical expert judgement, by the presence of MS-typical symptoms with objectifiable findings lasting more than 24 hours, without fever or infection. |
42 (+/-7d) post dose 1
|
|
Safety endpoint
Tidsramme: 42 (+/-7d) post dose 1
|
The investigators will analyse indicators of disease activity through different indicators only up to day 42 (+/-7d) post dose 1 - Activity in cerebral MRI scan (new or enlarging lesions or gadolinium uptake) |
42 (+/-7d) post dose 1
|
|
Safety endpoint
Tidsramme: 42 (+/-7d) post dose 1
|
The investigators will analyse indicators of disease activity through different indicators only up to day 42 (+/-7d) post dose 1 - Neurological assessment (EDSS) |
42 (+/-7d) post dose 1
|
|
Safety endpoint
Tidsramme: 42 (+/-7d) post dose 1
|
The investigators will analyse indicators of disease activity through different indicators only up to day 42 (+/-7d) post dose 1 - Multivariable blood biomarker based scores for MS disease activity (MSDA) and disease pathways (Octave Bioscience, USA) |
42 (+/-7d) post dose 1
|
|
Safety endpoint
Tidsramme: 42 (+/-7d) post dose 1
|
The investigators will analyse indicators of disease activity through different indicators only up to day 42 (+/-7d) post dose 1 - Vaccine reactogenicity (solicited and unsolicited local and systemic vaccine reactions) |
42 (+/-7d) post dose 1
|
Samarbeidspartnere og etterforskere
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Infeksiøs encefalitt
- Vektorbårne sykdommer
- Nevroinflammatoriske sykdommer
- Hjernesykdommer
- Sykdommer i sentralnervesystemet
- Sykdommer i nervesystemet
- Autoimmune sykdommer
- Sykdommer i immunsystemet
- Infeksjoner
- RNA-virusinfeksjoner
- Virussykdommer
- Demyeliniserende autoimmune sykdommer, CNS
- Autoimmune sykdommer i nervesystemet
- Demyeliniserende sykdommer
- Arbovirus infeksjoner
- Flavivirus infeksjoner
- Flaviviridae-infeksjoner
- Flåttbårne sykdommer
- Encefalitt, viral
- Virale sykdommer i sentralnervesystemet
- Infeksjoner i sentralnervesystemet
- Encefalitt
- Encefalitt, Arbovirus
- Multippel sklerose
- Encefalitt, flåttbåren
Andre studie-ID-numre
- 2025-01767
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .